FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer By Ogkologos - October 10, 2025 186 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the Guardant360 CDx assay as a companion diagnostic to identify patients with ESR1 mutations Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR FDA Grants Accelerated Approval to Amivantamab-vmjw for Metastatic NSCLC with EGFR... May 28, 2021 Mom’s Early-Stage Breast Cancer Discovered When She Undergoes Testing to Donate... August 21, 2019 EMA Recommends Granting a Conditional Marketing Authorisation for Ciltacabtagene Autoleucel April 22, 2022 ESMO Welcomes European Parliament Resolution Marking World Cancer Day February 11, 2026 Load more HOT NEWS Androgen Receptor May Explain Sex Differences in Melanoma Treatment Response Detecting multiple cancers with a ‘simple’ blood test: Where are we? First targeted treatment approved for advanced prostate cancer on NHS in... CancerLand Bookshelf : Loosen
